Sun Pharmaceutical Industries has announced plans to acquire US-based Organon & Co in an all-cash deal valued at about $11.75 billion, including debt. The Indian drugmaker will purchase all outstanding shares at $14 per share, marking a premium of over 24% to Organon’s last closing price. The deal ranks among the largest overseas acquisitions by […]Continue Reading
